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Abstract
Context—Unrecognized myocardial infarction (MI) is prognostically important but
electrocardiography (ECG), the main epidemiology tool for detection, is insensitive to MI.
Objective—Determine prevalence and mortality risk for unrecognized MI (UMI) detected by
cardiac magnetic resonance (CMR) or ECG.
Design—ICELAND MI is a cohort substudy of the Age, Gene/Environment Susceptibility-
Reykjavik Study (enrollment January 2004–January 2007) using ECG or CMR to detect UMI.
Setting—Community dwelling participants in Iceland over age 67.
Participants—936 participants (ages 67–93 years) including 670 who were randomly selected
and 266 with diabetes.
Main Outcome Measures—MI prevalence and mortality through September 1, 2011. Results
reported with 95% confidence limits and net reclassification improvement (NRI).
Results—Of 936 participants, 91 had recognized MI (RMI; 9.7% CI 8–12%), and 157 had UMI
by CMR (17%; CI 14–19%) which was more prevalent than the 46 UMI by ECG (5%; CI 4–6%,
p<0.001). Diabetic participants had more UMI by CMR than UMI by ECG (n=72; 21%; CI 17–
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26% vs. n=15; 4%; CI 2–7%, p<0.001). UMI by CMR was associated with atherosclerosis risk
factors, coronary calcium, coronary revascularization, and peripheral vascular disease. Over a
median of 6.4 years, 33% (CI 23–43%) of individuals with RMI died (30 of 91) and 28% (CI 21–
35%) with UMI died (44 of 157), both higher rates than the 17% (CI 15–20%) with no MI that
died (119 of 688). UMI by CMR improved risk stratification for mortality over RMI (NRI: 0.34;
CI 0.16–0.53). Adjusting for age, sex, diabetes, and RMI, UMI by CMR remained associated with
mortality (HR 1.45 CI 1.02–2.06, absolute risk increase (ARI) 8%) and significantly improved risk
stratification for mortality, NRI 0.16 (CI 0.01–0.31)) but UMI by ECG did not (HR 0.88, CI 0.45–
1.73 ARI −2%; NRI: −0.05; CI −0.17–0.05). Compared to those with RMI, participants with UMI
by CMR used cardiac medications such as statins less often (36%; CI, 28–43% or 56/157 vs.73%;
CI 63–82% or 66/91; p<0.001).
Conclusions—In a community-based cohort, the prevalence of UMI by CMR was higher than
the prevalence of recognized MI or UMI by ECG, and was associated with increased mortality
risk.
Introduction
The prevalence and prognosis of unrecognized myocardial infarction (MI) in older people
with and without diabetes may be higher than previously suspected in population studies.1–4
Advances in MI detection, such as cardiac magnetic resonance (CMR) with late gadolinium
enhancement (LGE), are more sensitive than prior methods.5 Ascertaining the prevalence of
unrecognized MI (UMI) in these groups is relevant since age and diabetes increase the risks
of coronary heart disease (CHD).6 Pathologic studies7 indicate that subclinical coronary
plaque rupture occurs frequently, particularly in diabetic individuals, which may culminate
in a high prevalence of UMI. Several population studies1–4 have described the prevalence of
UMI based on electrocardiography (ECG), but ECG has significant limitations such as
limited sensitivity that varies with infarct location8 and Q waves may resolve over time.9
Thus, the true prevalence of UMI may be significantly higher than appreciated in prior
epidemiology studies. CMR with late gadolinium enhancement (LGE) has been extensively
validated for the detection of MI,10 is more sensitive than SPECT11 or PET12 and therefore
is probably more sensitive than ECG. However, increased sensitivity is clinically important
when the new test better identifies those at risk for adverse events.
The specific aim of this study was to compare the prevalence and prognosis of recognized
and unrecognized MI diagnosed with CMR versus ECG in older diabetic and nondiabetic
participants participating in ICELAND MI, a substudy of the Age, Gene/Environment
Susceptibility-Reykjavik Study (AGES- Reykjavik). We hypothesized that UMI by CMR: 1)
would be more prevalent than UMI by ECG, in both diabetic and nondiabetic individuals 2)
would be associated with measures of atherosclerosis, and 3) would be significantly
associated with increased mortality risk.
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ICELAND MI is an epidemiologic cohort study of diabetic and nondiabetic individuals.
Participants were enrolled from January 2004 to January 2007, recruited from the AGES-
Reykjavik Study (n=5,764),13 a randomly selected population-based cohort of men and
women born between 1907 and 1935 who have been followed in Iceland since 1967 by the
Icelandic Heart Association. AGES–Reykjavik was approved by the National Bioethics
Committee in Iceland that acts as the institutional review board for the Icelandic Heart
Association (approval number VSN-00-063) and by the National Institute on Aging
Intramural Institutional Review Board. Participants were eligible to participate in ICELAND
MI if they provided written informed consent and were ineligible if they could not safely
receive CMR scans (e.g., implanted devices) or gadolinium contrast (e.g., severe kidney
disease). Participants were recruited from AGES-Reykjavik in two phases. The first phase
involved random recruitment, and a second phase recruited all eligible and willing
participants with diabetes.
Data Elements
Participants were characterized during three clinic visits.13 CMR studies occurred during a
separate exam that included ECG. Participant surveillance has been ongoing since 1967
through the Icelandic Heart Association13 and provided ascertainment of recognized MI.
Participants were defined as having a recognized MI when a history of MI was supported by
hospital records or surveillance records.13 Participants were defined as having an UMI by
ECG when there was evidence of MI by ECG criteria (Minnesota codes 1.1.1–1.2.8). 1 UMI
by CMR meant there was no prior MI by hospital records or by surveillance records, and
LGE involved the subendocardium in a coronary distribution. Other “atypical” patterns of
LGE were specifically not designated as MI, a strategy that yields sensitivities and
specificities >90% for MI detection.14–16 CMR studies were interpreted by cardiologists
blinded to clinical information.
Participants were further characterized with demographics, risk factors related to
atherosclerosis, other comorbidity, biochemical measurements from blood, coronary calcium
(Agatston scores), and ECG. Participants were classified as having diabetes according to
standard criteria (fasting glucose ≥7 mmol/L)17 or if they were already receiving treatment
for diabetes. All cause mortality was identified by review of hospital records as well as a
national mortality index with authentication of all death certificates13 through September 1,
2011.
Cardiovascular Magnetic Resonance Studies
CMR scans were performed on a 1.5T GE scanner (Milwaukee, WI) using a four-element
cardiac phased array coil. Typical cine SSFP scan parameters resulted in pixel dimensions of
1.8×2.1 mm, slice thickness 8 mm with 3 mm gap, and 30 images per cycle. Standard long
axis and short axis views were obtained to evaluate global and regional function. The
presence of MI was evaluated with a prospective, ECG gated, segmented, phase sensitive
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gradient echo inversion recovery sequence approximately 6–25 minutes after 0.1 mmol/kg
intravenous gadolinium (Magnevist, Berlex).18 LGE was designated MI by consensus of
cardiologists experienced in CMR.
Statistical analysis
Results are presented with 95% confidence intervals (CI). Categorical variables were
compared with the Chi-square or Fisher’s test. Continuous variables were compared with the
Wilcoxon rank-sum test. McNemar’s statistic tested whether CMR was more likely to detect
UMI than ECG. The log rank test compared survival curve strata. Binary response variables
were further analyzed by Cox regression survival analysis, and continuous variables were
analyzed by linear regression. Multivariable Cox models adjusted for variation in key
baseline characteristics included in prior epidemiologic studies using ECG: age, gender,
diabetes, recognized MI, and finally UMI by CMR or UMI by ECG. Proportional hazards
assumptions were verified by Schoenfeld residuals and time interaction terms. Absolute risk
increases were calculated by measuring the survival rate difference before and after
exponentiating the 7 year Kaplan-Meier survival rate in the reference group to the power of
the adjusted hazard ratio (HR) in the comparison group. The integrated discrimination index
(IDI) and net reclassification index (NRI) evaluated the added predictive ability of survival
models with the introduction of the UMI by CMR variable.19,20 Follow-up was enhanced by
hospital record information, a national mortality index with authentication of all death
certificates, a Minimum Data Set for Nursing Home patients, and Minimum Data Set for
Home-Care patients.13 Coronary artery calcium (CAC) was analyzed on the natural
logarithm scale, ln(CAC+1). Two sided p values <0.05 were considered significant. SAS
software (version 9.2) analyzed the data.
Results
Recruitment
For phase one, 839 individuals were invited and 702 enrolled. In phase two, 421 participants
with diabetes were invited and 290 people enrolled (1005 total). Thirty-five participants
declined CMR. Of those who underwent CMR (n=970), 34 participants had nondiagnostic
CMR scans due to: arrhythmia or inability to breath hold (n=14); claustrophobia (n=7);
inability to gate cardiac images (n=3), technical issues with reconstruction and data transfer
(n=9); or artifact from spinal implants (n=1). These participants were excluded leaving a
final cohort of 936 participants. Survivors were followed for a median of 6.6 years (range
4.6– 7.7 yrs).
Baseline Characteristics
The median age was 76 years (range 68 to 94 years), and 52% (CI 49–55%) were women
(484 of 936). Baseline characteristics are summarized in Table 1. ICELAND MI participants
randomly selected in phase 1 had characteristics almost identical to the AGES-Reykjavik
participants (Supplementary eTable 1).
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Prevalence of Myocardial Infarction using Cardiovascular Magnetic Resonance and ECG
While 91 of 936 participants (9.7% CI, 8–12%) had recognized MI, the prevalence of UMI
by CMR was even higher 157 of 936 (17%, CI, 14–19%; p<0.001) as shown in Table 2.
Those with diabetes had a higher prevalence of UMI by CMR than those without diabetes
(n=72; 21%, CI 17–26% vs. n=85; 14%, CI 11–17%, p<0.001). Examples are shown in
Figure 1.
CMR detected 157 UMI which was more than the 46 UMI by ECG (prevalence by CMR
17%, CI 14–19% vs. ECG 5%, CI 4–6%, respectively, p<0.001). There were 27 participants
(3%, CI 2–4%) with UMI by ECG that exhibited no MI on CMR, and there were 138 (15%,
CI 12– 17%) individuals who had UMI by CMR yet did not meet criteria for UMI by ECG
(p<0.001). In the randomly sampled cohort (n=670), 61 (9%, CI 7–11%) had recognized MI
and 97 (14%, CI 12–17%) had UMI by CMR whereas only 35 (5%, CI 4–7%) had UMI by
ECG, significantly less than UMI by CMR (p<0.001).
Associations of Unrecognized MI by CMR and Recognized MI with Atherosclerosis and
Diabetes
Coronary artery disease risk factors were more prevalent in participants with UMI compared
with those with no MI. Compared to those without MI, participants with UMI were more
frequently male, were slightly older, and had more hypertension and diabetes (Table 3).
Similarly, those with UMI had more atherosclerosis with significantly higher coronary
calcium scores than those without MI (Table 3). Overall, coronary calcium showed a
significant graded relationship to the presence of MI, where participants with UMI had
coronary calcium intermediate between those without MI and those with clinically
recognized MI (Table 3).
There was also a graded relationship between the likelihood of revascularization and MI
status (Table 3). For 26 of 72 diabetic (36%, CI 25–47%) and 18 of 85 nondiabetic (21%, CI
12– 30%) participants with UMI had prior coronary revascularization. Excluding those with
prior coronary revascularization (n=139), diabetic and nondiabetic participants still had high
rates of UMI (46/273 or 17%, CI 12–21% versus 67/524 or 13%, CI 10–16%, respectively).
Thus, UMI was associated with atherosclerosis risk factors, coronary calcium, and treatment
for atherosclerosis. Other characteristics of those with UMI by CMR are also provided in
Table 3.
Prognosis of Recognized and Unrecognized MI by ECG or CMR
Over a median follow-up of 6.4 years (interquartile range 4.9–7.0 years), 30 of 91
participants with recognized MI died (33%, CI 23–43%) and 44 of 157 with UMI by CMR
died (28% CI 21–35%) which were both significantly higher rates than the 17% (CI 15–
20%) with no MI that died (119 of 688). Both UMI by CMR and recognized MI had higher
mortality compared to those without MI (HR 1.81, CI 1.28–2.56; absolute risk increase
13%, and HR 2.20, CI 1.48–3.29, absolute risk increase 19%, respectively). UMI by CMR
improved mortality risk stratification beyond RMI (category free NRI: 0.34; CI 0.16–0.53).
UMI detected by ECG was not associated with higher mortality (HR 0.95, CI 0.49–1.87,
absolute risk increase; −1%). Unadjusted Kaplan-Meier survival curves for those without
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MI, those with UMI by CMR, and those with clinically recognized MI are shown in Figure
2. Five years after the CMR scan, the absolute mortality rates were: 12% (CI 9–14%) for
those without MI, 23% (CI 16–29%) with unrecognized MI by CMR, and 23% (CI 17–30%)
in those with recognized MI. This culminated in approximately a 10% difference in absolute
mortality rates between those with and without MI (eTable2).
After adjusting for age, gender, diabetes, and recognized MI, UMI by CMR remained
associated with mortality (HR 1.45 CI 1.02–2.06; absolute risk increase 8%), but UMI by
ECG was not associated with mortality (HR 0.88 (CI 0.45–1.73; absolute risk increase
−2%). Similarly, UMI by CMR significantly improved the classification of those at risk for
mortality (category free NRI 0.16; CI 0.01–0.31, p=0.042) but UMI by ECG did not (NRI:
−0.05; CI −0.17– 0.05). Finally, UMI by CMR significantly improved mortality risk
stratification (absolute IDI 0.008, CI 0.004–0.013, p<0.001), but UMI by ECG did not
improve mortality risk stratification (IDI 0.000 (CI −0.001−0.001; p=0.71).
Treatment Differences
We observed more use of aspirin, beta-blocker, and statin medications in those with UMI by
CMR compared to those without MI. Yet, the use of cardiac medications was significantly
less in those with UMI compared to those with recognized MI (Table 3). Roughly half of
those with UMI were taking aspirin, whereas less than half were taking statins or beta-
blockers.
Discussion
Using CMR with a conservative interpretation scheme to detect MI in a cohort of
community-dwelling, older people, we found a high overall prevalence of UMI. More
participants had UMI (17%) than recognized MI (9.7%) resulting in a much higher fraction
of the population being identified as having an MI (26%). Individuals with diabetes had a
particularly high prevalence of UMI (21%), underscoring the designation of diabetes as a
coronary risk equivalent,6 but the pattern of more UMI than recognized MI was also true in
those without diabetes. Participants with UMI by CMR had higher coronary calcium, a
higher prevalence of atherosclerotic disease, and a higher prevalence of traditional risk
factors compared to those with no MI. CMR was more sensitive than ECG in detecting
UMI. UMI detected by CMR was associated with subsequent mortality over 6–7 years, but
UMI detected by ECG was not. Compared with those with recognized MI, participants with
UMI by CMR received fewer prescriptions for medications used to prevent cardiovascular
events. Considering the prevalence of UMI (17%) was higher than the prevalence of RMI
(10%), many people might conceivably benefit from more intensive preventive “post-MI”
therapy, but this hypothesis remains untested.
Several factors may contribute to the high prevalence of UMI. First, subclinical coronary
plaque rupture occurs frequently, particularly in diabetic individuals.21 CMR may detect the
myocardial sequelae of coronary plaque rupture or coronary plaque erosion21 that either
spontaneously reperfused or were non-occlusive. Second, symptom variation in acute MI 22
may lead patients or their clinicians to attribute MI symptoms to noncardiac causes. Third,
given their propensity to be clinically detected, recognized MI may be more severe than
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UMI and impart greater lethality.23,24 Survivor bias may also have increased the proportion
of those with UMI in this study, but survivors are the only people eligible for “post-MI”
secondary prevention.
The high prevalence of UMI highlights the advantages of using CMR for detection in
epidemiology studies. While the prevalence of UMI by ECG was similar to prior population
studies,1–4 ECG was much less sensitive for detecting UMI than CMR. Prior population
studies probably underestimate the prevalence of MI and particularly UMI since they relied
on ECG for detection. The mortality risk associated with UMI by ECG is less than previous
reports;1,3 smaller sample size, survivor bias, and different health care practices may be
factors.
The increased mortality risk associated with UMI detected by CMR in a community based
cohort of older individuals is an important finding of this study, since we document a high
prevalence of UMI. In fact, we found that the majority of all MI were clinically
unrecognized, suggesting a significant public health burden. This association between
prevalent UMI and mortality is novel, since prior epidemiology studies relying on ECG data
indicated that a minority of MI are clinically unrecognized.1–4 Our study is also the first
epidemiology study to associate coronary calcium with evident MI on CMR LGE images.
While another smaller study employing LGE in 248 individuals also reported that most MI
were unrecognized, the study only sampled 75 year old individuals and cannot determine the
association with mortality controlling for age.25 UMI appears to represent an intermediate
phenotype in the evolution of coronary heart disease, given its graded association with
atherosclerosis risk factors, coronary calcium, overt atherosclerosis, and subsequent
mortality risk.
Other studies have associated UMI identified by CMR with adverse outcomes, but these
studies were not community-based epidemiology studies; instead, they were conducted in
referral populations with higher baseline risk and inherent biases.24,26,27 The relative risk of
UMI may be higher in these studies due to referral biases not present in our community
based population study. Nonetheless, the current study indicates that the adverse outcomes
associated with UMI extend to the community. Our study also indicates that CMR is more
robust at detecting MI and more strongly associated with mortality compared to ECG – an
observation with important implications for future epidemiology studies of UMI.
Several lines of evidence establish that the designation of UMI represents true
MI.10,14,16,28,29 First, CMR scans were interpreted conservatively. Specifically, “atypical”
patterns of enhancement seen with conditions unrelated to coronary disease were not
designated as MI. Second, the prevalence of risk factors for CHD or established
atherosclerotic disease documented multiple associations of UMI by CMR with
atherosclerosis. Kim et al. have also shown associations between coronary disease and
UMI.27 Finally, the association between UMI detected by LGE and mortality also supports
the diagnosis of MI.
This investigation also suggests limitations in current prevention strategies. Herein we report
a burden of MI in community dwelling older individuals that is higher than previously
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appreciated. In fact, the burden of UMI was higher than the total burden of recognized MI,
and prescription of cardioprotective medications were less than for participants with
recognized MI. The high prevalence of MI specifically in diabetic individuals confirms their
increased vulnerability. Less than one third of those with UMI by CMR had prior
revascularization to establish coronary disease and trigger secondary prevention strategies.
Detection of UMI by CMR may provide an opportunity optimize management of these
vulnerable individuals. Further study is needed to define optimal treatment strategies for
those with UMI.
Limitations
The AGES–Reykjavik cohort provides results that are most applicable to Caucasian
participants, and may not extend to other ethnicities. The sensitivity of CMR for detecting
chronic MI using a 0.1 mmol/kg gadolinium contrast dose in our study may be lower
compared to higher doses.16 However, if our study actually had low sensitivity, then the
‘true’ prevalence of MI would be higher. Mitigating the issue of contrast dose, the phase
sensitive LGE18 method used in this study has better signal to noise ratio at low contrast
doses than conventional LGE methods. In the minority of participants with both UMI and
prior coronary revascularization, we could not ascertain whether UMI occurred
independently or as a clinically unappreciated consequence of revascularization.
Nonetheless, revascularization complications do not explain the high prevalence of UMI
since the prevalence of UMI in diabetic and nondiabetic participants remained high even
after excluding prior coronary revascularization. We also did not examine more subtle ECG
changes that may be associated with MI. Risk adjustment was limited. This study was
designed to demonstrate comparable prognosis between UMI and recognized MI; it was not
powered to permit extensive risk adjustment for all baseline differences.
Conclusions
Older individuals in the community had a high prevalence of MI, especially those with
diabetes. Most MI were unrecognized, despite associations with atherosclerosis, risk factors,
and health care advances. CMR with LGE detected more UMI and was more strongly
associated with mortality than ECG. UMI detected by CMR with LGE was associated with
mortality similar to recognized MI. Participants with UMI received less cardiac medications
than those with recognized MI.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. CMR examples of recognized MI (A), no MI (B), and unrecognized MI (C and D)
Panel A demonstrates a recognized myocardial infarction involving the anterior and
anteroseptal segments in the typical left anterior descending artery distribution as seen on
late gadolinium enhancement imaging (arrow) with the corresponding diastolic cine frame
on the right. Panel B demonstrates a participant with no evidence of myocardial infarction
on late gadolinium enhancement imaging. The myocardium is uniformly dark (“nulled”) on
the late gadolinium enhancement image (left). Panel C demonstrates an unrecognized
myocardial infarction in the basal inferolateral wall on late gadolinium enhancement
imaging (arrow) with the corresponding end-diastolic cine frame on the right. Panel D
demonstrates two unrecognized myocardial infarctions in different coronary territories in the
same participant. There is a small myocardial infarction in the inferolateral wall (arrow)
corresponding to the left circumflex artery territory and a larger myocardial infarction
involving the anterior and anteroseptal segments (arrow) corresponding to left anterior
descending artery territory. The corresponding end-diastolic cine frame is shown on the
right.
Schelbert et al. Page 11






















Figure 2. Mortality curves according to myocardial infarction status
The mortality was similar (p=0.399) between recognized and unrecognized MI, and the
mortality was significantly worse (p<0.001) for those with unrecognized MI versus those
without MI based on the log rank test.
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Table 1
Baseline characteristics of participants.
Variable Number (Percentage) or
Median
(IQR for continuous variables)
N=936
Patient Characteristics
Age, median (IQR), y 76 (72–81)
Women, No. (%, CI) 484 (52%, 49–55%)
BMI, median (IQR) 27 (25–30)
Risk factors for coronary heart disease
Hypertension, No. (%, CI) 629 (67%, 64–70%)
Prior or current smoking, No. (%, CI) 560 (60%, 57–63%)
Family history of MI, No. (%, CI) 334 (36%, 33–39%)
Diabetes, No. (%, CI) 337 (36%, 33–39%)
Hypercholesterolemia, No. (%, CI) 421 (45%, 42–48%)
History of atherosclerosis
  Coronary disease (Hospital records)
  Prior MI, No. (%, CI) 91 (10%, 8–12%)
  Prior coronary revascularization, No. (%, CI) 139 (15%, 13–17%)
  Other atherosclerotic disease
  Peripheral arterial disease, No. (%, CI) 18 (2%, 1–3%)
  Stroke, No. (%, CI) 52 (6%, 4–7%)
Laboratory Results
eGFR, median (IQR) mL/min per 1.73 m2 69 (59–82)
Total Cholesterol, median (IQR), mg/dL* 208 (178–240)
HDL Cholesterol, median (IQR), mg/dL* 56 (46–68)
LDL Cholesterol, median (IQR), mg/dL* 128 (99–158)
Triglycerides, median (IQR), mg/dL* 98 (75–135)
Coronary calcium score, median (IQR), Agatston† 361 (74–974)
*
To convert to SI units, multiply cholesterol values by 0.0259, and triglyceride values by 0.0113.
†
The coronary calcium scores ranged from 0–7333. Coronary artery calcification occurs in atherosclerotic arteries and is absent in the normal
vessel wall. Higher coronary calcium scores, measured by the Agatston method from CT scans, correlate with higher risks of coronary events.
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Table 2
Prevalence of recognized and unrecognized myocardial infarction (MI) by CMR or ECG stratified by diabetes
status. UMI by CMR were observed roughly twice as often as recognized MI. The prevalence of MI with the
addition of ECG was significantly higher than the prevalence without ECG, but still significantly less than the
increased prevalence with the addition of CMR (p<0.01 for both).








No MI 688 (74%, 71–76%) 228 (68%, 63–73%) 460 (77%, 73–80%)
Clinically Recognized MI 91 (10%, 8–12%) 37 (11%, 8–14%) 54 (9%, 7–11%)
Unrecognized MI by ECG 46 (5%, 4–6%) 15 (4%, 2–7%) 31 (5%, 3–7%)
Unrecognized MI by CMR 157 (17%, 14–19%) 72 (21%, 17–26%) 85 (14%, 11–17%)
Cumulative MI by ECG 137 (15%, 12–17%) 52 (15%, 12–19%) 85 (14%, 11–17%)
Cumulative MI by CMR 248 (27%, 24–29%) 109 (32%, 27–37%) 139 (23%, 20–27%)
Abbreviations: CMR, cardiac magnetic resonance; ECG, electrocardiography; MI, myocardial infarction.
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Table 3











Age, median (IQR), y 76 (72–80) 77 (74–83) 78 (74–82) <0.001
Women, No. (%, CI) 395 (57%, 54–61%) 57 (36%, 29–44%)* 32 (35%, 25–45%) <0.001
BMI, median (IQR) 27 (25–30) 28 (25–30) 27 (24–31) 0.80
Risk factors for coronary heart disease
Hypertension, No. (%, CI) 422 (61%, 58–65) 124 (79%, 73–85%)*† 83 (91, 85–97%) <0.001
Prior or current smoking, No. (%, CI) 391 (58%, 54–61%) 98 (62%, 55–70%) 65 (71%, 62–81%) 0.033
Family history of MI, No. (%, CI) 237 (34%, 31–38%) 56 (36%, 28–43%) 41 (45%, 35–55%) 0.14
Diabetes, No. (%, CI) 228 (33%, 30–37%) 72 (46%, 38–54%)* 37 (41%, 31–51%) 0.007
Hypercholesterolemia, No. (%, CI) 297 (43%, 39–47%) 72 (46%, 38–54%) 52 (57%, 47–67%) 0.041
History of atherosclerosis
Prior coronary revascularization, No. (%) 42 (6%, 4–8%) 44 (28%, 21–35%)*† 53 (58%, 48–68%) <0.001
Peripheral arterial disease, No. (%) 8 (1%, 0–2%) 6 (4%, 1–7%)* 4 (4%, 0–9%) 0.018
Stroke, No. (%) 33 (5%, 3–6%) 11 (7%, 3–11%) 8 (9%, 3–15%) 0.20
Laboratory Results
eGFR, median (IQR) mL/min per 1.73 m2 70 (59–82) 68 (58–81) 64 (53–74) 0.004
Total Cholesterol, median (IQR), mg/dL* 216 (185–243) 201 (170–239)*† 178 (154–205) <0.001
HDL Cholesterol, median (IQR), mg/dL* 58 (47–69) 53 (45–63)* 51 (42–59) <0.001
LDL Cholesterol, median (IQR), mg/dL* 134 (108–162) 120 (91–157) *† 98 (77–128) <0.001
Triglycerides, median (IQR), mg/dL* 95 (73–132) 108 (79–148)* 104 (73–145) 0.008
Coronary calcium score, median (IQR), Agatston 227 (50–693) 792 (263–1713)*† 1133 (654–2159) <0.001
Medications
Aspirin, No (%, CI) 215 (31%, 28–35%) 81 (52%, 44–59%)*† 74 (81%, 73–89%) <0.001
Beta blocker, No (%, CI) 237 (34%, 31–38%) 70 (45%, 37–52%)*† 70 (77%, 68–86%) <0.001
Statins, No (%, CI) 153 (22%, 20–25%) 56 (36%, 28–43%)*† 66 (73%, 63–82%) <0.001
ACE Inhibitors or Angiotensin receptor blockers, No (%,
CI)
132 (19%, 16–22%) 42 (27%, 20–34%)* 26 (29%, 19–38%) 0.0084
CMR characteristics
Ejection fraction (%), median (IQR) 63 (58–67) 60 (51–65)*† 53 (42–61) <0.001
End diastolic volume index, ml/m2) 98 (87–111) 109 (92–124)*† 113 (96–147) <.001
Left ventricular mass index, g/m2 72 (62–83) 83 (70–95)* 83 (69–102) <.001
*
Significantly different compared to individuals without MI (p<0 .05). For coronary calcium, these differences persisted even after adjusting for
age and gender.
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†
Significantly different compared to those with recognized MI (p<0.05). For coronary calcium, these differences persisted even after adjusting for
age and gender.
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